Top Markets
Coin of the day
Spectrum Pharmaceuticals, Inc. Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc.

SPPI
Rank in Stocks #21095
Spectrum Pharmaceuticals, Inc. operates as a biopharmaceutical firm, primarily... Spectrum Pharmaceuticals, Inc. operates as a biopharmaceutical firm, primarily engaged in the research, development, and market introduction of innovative drug products for cancer and blood disorders. Its robust pipeline features Eflapegrastim, an advanced, long-acting granulocyte colony-stimulating factor designed to address chemotherapy-induced neutropenia. Also under development is Poziotinib, a distinct irreversible tyrosine kinase inhibitor intended for non-small cell lung cancer tumors exhibiting various mutations. Furthermore, Anti-CD20-IFNa, an antibody-interferon fusion molecule targeting CD20, is progressing through Phase I development for patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. The company maintains key collaborative agreements, such as co-development, commercialization, and in-licensing arrangements with Hanmi Pharmaceutical Co. Ltd., a patent and technology license with The University of Texas M.D. Anderson Cancer Center, and an in-license pact with ImmunGene, Inc. Founded in 1987, and initially known as NeoTherapeutics, Inc. before its name change in December 2002, Spectrum Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Share Price
$1.03
Last synced: 2023-07-31
Market Cap
$115.13M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Spectrum Pharmaceuticals, Inc. (SPPI)

Category

Earnings for Spectrum Pharmaceuticals, Inc. (SPPI)
Earnings in 2026 TTM: 0
According to Spectrum Pharmaceuticals, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Spectrum Pharmaceuticals, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH